Comparison of the Efficacy and Safety of Transarterial Chemoembolization Plus Microwave Ablation versus Surgical Resection in Patients with Solitary Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166.
   PubMed Web of Science ®Google Scholar
• Liu PH, Su CW, Hsu CY, et al. Solitary large hepatocellular carcinoma: staging and treatment strategy. PLoS One. 2016;11(5):e0155588.
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim JY, Lee JH, et al. Long-term outcomes of transarterial radioembolization for large single hepatocellular carcinoma: a comparison to resection. J Nucl Med. 2021;63:1215.
   PubMed Web of Science ®Google Scholar
• Ding X, Sun W, Chen J, et al. Percutaneous radiofrequency ablation combined with transarterial chemoembolization plus sorafenib for large hepatocellular carcinoma invading the portal venous system: a prospective randomized study. Front Oncol. 2020;10:578633.
   PubMed Web of Science ®Google Scholar
• Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ, Wu F. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009;249(1):118–123.
   PubMed Web of Science ®Google Scholar
• Zhao HC, Wu RL, Liu FB, et al. A retrospective analysis of long term outcomes in patients undergoing hepatic resection for large (>5 cm) hepatocellular carcinoma. HPB. 2016;18(11):943–949.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128–139.
   PubMed Web of Science ®Google Scholar
• Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000;214(3):761–768.
   PubMed Web of Science ®Google Scholar
• Abdelaziz AO, Nabeel MM, Elbaz TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50(4):479–484.
   PubMed Web of Science ®Google Scholar
• Xue T, Le F, Chen R, et al. Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Med Oncol. 2015;32(3):64.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yu H, Qi L, et al. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia. 2022;39(1):455–465.
   PubMed Web of Science ®Google Scholar
• Chen QW, Ying HF, Gao S, et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2016;40(3):309–314.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma L, Yuan Z, Zheng J, Li W. Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus: a retrospective study. PLoS One. 2018;13(7):e0201525.
   PubMed Web of Science ®Google Scholar
• Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies. Cancers. 2020;12:7.
   Web of Science ®Google Scholar
• Gui CH, Baey S. Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma – a meta-analysis. Euro J Surg Oncol. 2020;46(5):763–771.
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783–797.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wu J, He M, et al. Comparison of transcatheter arterial chemoembolization combined with radiofrequency ablation or microwave ablation for the treatment of unresectable hepatocellular carcinoma: a systemic review and meta-analysis. Int J Hyperthermia. 2020;37(1):624–633.
   PubMed Web of Science ®Google Scholar
• Laska E, Meisner M, Wanderling J. A maximally selected test of symmetry about zero. Stat Med. 2012;31(26):3178–3191.
   PubMed Web of Science ®Google Scholar
• Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: the current status. Surgeon. 2020;18(3):178–186.
   PubMed Web of Science ®Google Scholar
• Jung YK, Jung CH, Seo YS, et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol. 2016;31(2):467–474.
   PubMed Web of Science ®Google Scholar
• Zhong JH, Pan LH, Wang YY, et al. Optimizing stage of single large hepatocellular carcinoma: a study with subgroup analysis by tumor diameter. Medicine. 2017;96(15):e6608.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36.
   PubMed Web of Science ®Google Scholar
• Jin YJ, Lee JW, Choi YJ, et al. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18(3):555–561.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma L, Sheng S, Yuan Z, Zheng J, Li W. Combination therapy of TACE and CT-guided partial hepatic segment ablation for liver cancer. Minim Invasive Ther Allied Technol. 2018;27(6):355–364.
   PubMed Web of Science ®Google Scholar
• Liu B, Li W, Zheng J. Safety and efficacy of the combination therapy of transcatheter arterial chemoembolization and ablation for hepatocellular carcinoma with inferior vena cava tumor thrombus: a consecutive case series. J Cancer Res Ther. 2020;16(5):1186–1190.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev. 2022;1:CD013345.
   PubMedGoogle Scholar
• Zuo TY, Liu FY, Wang MQ, Chen XX. Transcatheter arterial chemoembolization combined with simultaneous computed tomography-guided radiofrequency ablation for large hepatocellular carcinomas. Chin Med J. 2017;130(22):2666–2673.
   PubMed Web of Science ®Google Scholar
• Kagawa T, Koizumi J, Kojima S-I, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116(15):3638–3644.
   PubMed Web of Science ®Google Scholar
• Kim JW, Shin SS, Kim JK, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol. 2013;14(4):626–635.
   PubMed Web of Science ®Google Scholar
• Pan T, Mu L-W, Wu C, et al. Comparison of combined transcatheter arterial chemoembolization and CT-guided radiofrequency ablation with surgical resection in patients with hepatocellular carcinoma within the up-to-seven criteria: a multicenter case-matched study. J Cancer. 2017;8(17):3506–3513.
   PubMed Web of Science ®Google Scholar
• Yuan H, Cao P, Li H-L, et al. Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. Cancer Manag Res. 2018;10:5545–5552.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086–1092.
   PubMed Web of Science ®Google Scholar
• Hu H, Qi S, Zeng S, et al. Importance of microvascular invasion risk and tumor size on recurrence and survival of hepatocellular carcinoma after anatomical resection and non-anatomical resection. Front Oncol. 2021;11:621622.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Zhou Z, Ma Z, et al. Prognostic stratification based on a novel nomogram for solitary large hepatocellular carcinoma after curative resection. Front Oncol. 2020;10:556489.
   PubMed Web of Science ®Google Scholar
• Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma”. Review article. Ann Hepatol. 2021;22:100249.
   PubMed Web of Science ®Google Scholar
• Lin S, Hu S, Ran Y, Wu F. Neutrophil-to-lymphocyte ratio predicts prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2021;10(4):1667–1678.
   PubMed Web of Science ®Google Scholar
• Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–2167.
   PubMed Web of Science ®Google Scholar
• Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40(3):228–242.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234(6):8509–8521.
   PubMed Web of Science ®Google Scholar
• Bian J, Lin J, Long J, et al. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy. Am J Cancer Res. 2020;10(12):4585–4606.
   PubMed Web of Science ®Google Scholar
• Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: from molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol. 2022;28(21):2251–2281.
   PubMed Web of Science ®Google Scholar
• Lin XJ, Lao XM, Shi M, Li SP. Changes of HBV DNA after chemoembolization for hepatocellular carcinoma and the efficacy of antiviral treatment. Dig Dis Sci. 2016;61(9):2465–2476.
   PubMed Web of Science ®Google Scholar
• Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy? Ann Surg Oncol. 2014;21(3):1010–1015.
   PubMed Web of Science ®Google Scholar